BioLargo, Inc., an environmental engineering firm, has reported significant progress in its efforts to remediate PFAS-contaminated water using its patented Aqueous Electrostatic Concentrator (AEC) at a municipal facility in Lake Stockholm, New Jersey. More than two million gallons of contaminated water have been treated in just over six months, affirming the system's capabilities.
The AEC, installed in January 2026, has demonstrated remarkable effectiveness in eliminating over 99% of PFAS chemicals from drinking water. The system consistently meets or surpasses the stringent standards set by the New Jersey Department of Environmental Protection (NJDEP) and the U.S. Environmental Protection Agency (EPA). Notably, its unique technology generates significantly less waste than traditional methods.
The performance of the AEC is being evaluated under a 12-month monitoring program overseen by the NJDEP and the EPA. This ongoing assessment aims to ensure the system’s continued compliance with established health and safety guidelines.
With its initial success at Lake Stockholm, BioLargo is positioning the AEC as a commercial reference site for potential customers and engineers looking to validate the system’s effectiveness and operational savings. The company’s President and CEO, Dennis P. Calvert, emphasized the importance of this installation as a clear demonstration that the AEC works effectively. He noted, “The question is no longer ‘does it work’, but rather ‘where and how quickly’ the AEC can be deployed next.”
PFAS, often referred to as “forever chemicals,” are notorious for their environmental persistence and potential health risks. Once introduced into the human body, these substances can accumulate in various organs and tissues, leading to potential health issues such as certain cancers, hormonal disruptions, and developmental concerns in children. Given their widespread presence in the bloodstream of the majority of Americans tested, effective remediation strategies are increasingly crucial.
BioLargo is actively pursuing partnerships to broaden the application of the AEC technology. An existing memorandum of understanding with Aquatech aims to combine its PFAS treatment capabilities with BioLargo's system, expanding the AEC's utility beyond municipal drinking water to address other forms of PFAS contamination, including industrial wastewater and landfill leachate.
BioLargo's AEC has treated more than two million gallons of PFAS-contaminated water at the municipal drinking water facility in Lake Stockholm, New Jersey, since its installation in January 2026. It consistently meets or exceeds the regulatory standards set by both the New Jersey Department of Environmental Protection (NJDEP) and the U.S. Environmental Protection Agency (EPA) for PFAS removal.
The AEC claims to remove more than 99% of PFAS chemicals from water and has consistently met the regulatory standards of NJDEP and U.S. EPA maximum contaminant levels. However, the long-term performance and reliability of the AEC in different environments and scales remains to be fully demonstrated.
The AEC generates a smaller volume of waste compared to traditional methods like granular activated carbon or ion exchange systems, which often produce large amounts of PFAS-laden spent media. However, the long-term operational costs and environmental implications of using the AEC compared to established methods remain to be thoroughly evaluated.
The AEC's performance is being monitored under a 12-month program by both the NJDEP and the U.S. EPA. This ongoing evaluation aims to ensure that the AEC continues to meet the necessary regulatory standards for PFAS removal.
PFAS exposure has been linked to various health issues, such as certain cancers, weakened immune systems, thyroid disruption, and developmental damage in children. It is important to note that while these health effects are documented, individual exposure levels can vary widely.
BioLargo faces several risks including regional economic conditions affecting consumer purchasing decisions, competition in a rapidly changing market, and dependency on distributor performance. These risks could impact the company's business and financial results.
The partnership with Aquatech is positioned to enhance the application of BioLargo's AEC beyond municipal drinking water to address a wider array of PFAS challenges. This collaboration could potentially expand the commercial reach of the AEC, although the specific outcomes are yet to be realised.
You can find more information about BioLargo, Inc., and its offerings on their website at www.BioLargo.com, and for specific information regarding their equipment solutions, visit www.bestpfastreatment.com.